Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin.
Electrochemotherapy is an anti-tumour treatment that utilizes locally delivered electric pulses to increase cytotoxicity of chemotherapeutic drugs. The aim of our study was to determine whether anti-tumour effectiveness of electrochemotherapy with cisplatin is a consequence of increased plasma membrane permeability caused by electroporation that enables cisplatin binding to DNA. For this purpose, anti-tumour effectiveness of electrochemotherapy was evaluated on SA-1 tumours treated with electric pulses 3 min after intravenous injection of cisplatin (4 mg kg(-1)). Anti-tumour effectiveness was correlated with platinum accumulation in tumours and the amount of platinum bound to DNA, as determined by atomic absorption spectrometry. In tumours treated with electrochemotherapy, cell kill was increased by a factor of 20 compared with treatment with cisplatin only, as determined from tumour growth curves. The amount of platinum bound to DNA and platinum content in the tumours treated by electrochemotherapy was approximately two times higher than in cisplatin-treated tumours. Based on our results, we conclude that in vivo application of electric pulses potentiates anti-tumour effectiveness of cisplatin by electroporation that consequently results in cisplatin increased delivery into the cells. In addition, besides electroporation, immune system and tumour blood flow changes could be involved in the observed anti-tumour effectiveness of electrochemotherapy.
Cemazar
M
M
Institute of Oncology, Ljubljana, Slovenia.
Miklavcic
D
D
Scancar
J
J
Dolzan
V
V
Golouh
R
R
Sersa
G
G
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D002945:Cisplatin / Q000378:metabolism / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018736:DNA Adducts / Q000378:metabolism; D004599:Electric Stimulation Therapy; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D007275:Injections, Intravenous; D051379:Mice; D008805:Mice, Inbred A; D009336:Necrosis; D010984:Platinum / Q000378:metabolism*
D000970:Antineoplastic Agents; D018736:DNA Adducts; C057270:cisplatin-DNA adduct; D010984:Platinum; D002945:Cisplatin